<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Lung Nodule Testing

nodifylung-654

Designed to help physicians quickly and accurately decipher the risk of malignancy of a lung nodule from a single blood draw.

One single blood draw. Two ways to help decipher the risk of malignancy of a lung nodule.


How does Nodify Lung testing work?


Why add proteomics to clinical risk assessment?

nodify-cdt-line-540

Helps identify patients who may benefit from timely intervention with results in one day.

LEARN MORE ABOUT NODIFY CDT™

nodify-xl2-line-540

Helps identify patients who may benefit from computed tomography (CT) surveillance with results in one week.

LEARN MORE ABOUT NODIFY XL2™

Cohesive Testing Strategy That Reclassifies Risk of Malignancy

Risk Groups from the American College of Chest Physicians (ACCP) Guidelines for New Pulmonary Nodules1*​

img-risk-assessment2

 

Which patients are eligible for Nodify LungTM testing?

Order Nodify Testing

Nodify Lung testing is intended for patients with incidental lung nodules:​

  • R91.1 (solitary nodule) or R91.8 (multiple nodules) ICD-10 code​
  • ≥40 years old​
  • 8-30 mm nodule​
  • ≤65% risk of malignancy (Solitary Pulmonary Nodule calculator (Mayo Model)1)​
  • No previous diagnosis of cancer ​
    Patients are eligible for Nodify XL2 testing if history of non-lung cancer is >5 years and risk of malignancy is ≤50%

Nodify Testing Can Help You

Reclassify low to moderate risk lung nodules as high or very low risk of malignancy prior to bronchoscopy.
Identify lung cancer earlier and reduce unnecessary procedures on benign nodules.​
Support shared-decision making with an individualized risk assessment.​


Simple. Dynamic. Reassuring.

There is no out of pocket expense for Medicaid and covered Medicare patients for Nodify Lung™ testing

Learn more

Interested in ordering a Nodify LungTM test kit?

The Nodify Lung Blood Specimen Collection Kit is used for both the Nodify CDT™ and the Nodify XL2™ proteomic tests.

REQUEST A KIT
WATCH INSTRUCTIONAL VIDEO

Get in touch

Contact Us

Data Library

Discover More
  1. Gould M, Donington J, Lynch W, et al. Evaluation of Individuals with Pulmonary Nodules: When is it Lung Cancer? CHEST. 2013; 143(5): e93S-e120S.

* According to the ACCP guidelines, patients with a Very Low risk of malignancy should be considered for CT surveillance and patients with a High risk should receive a stage evaluation and appropriate intervention.